Investigators say that a preliminary analysis found that the therapy hit its primary outcome on the mortality rate.
Bayer Healthcare touted upbeat data from a pair of late-stage studies of an investigational drug targeting chin fat, setting the stage for the giant to step into growing aesthetic treatment market. And the results provide a victory from Kythera, which licensed the injected drug to Bayer for markets outside the U.S. and Canada.
The Alzheimer's drug bapineuzumab failed miserably in one of the biggest Phase III studies of the year. But the drug--once a megablockbuster hopeful at Johnson & Johnson and Pfizer--had an impact on key biomarkers for the disease, leading investigators to urge a major new effort to see if the drug could work to delay the onset of the memory-wasting affliction.
Novartis has snapped in the last piece of an intricate and ambitious data puzzle for QVA149 and says it all points to near-term regulatory filings for the combo LAMA/LABA lung drug in Europe and Japan.
AstraZeneca has been under the gun recently for paying some hefty prices on a string of business deals for new products. But after reporting another dismal set of quarterly earnings--with sales plunging 21% on a combination of generic competition and European-style economizing--the pharma giant is signaling that the deal-making has just begun.
Research Triangle Park, NC-based Chimerix has inked its first big partnership, reaping a $17.5 million upfront payment and a promise of up to $151 million more from Merck, which gains rights to a mid-stage antiviral--CMX157--which has prospects as a new addition to future HIV cocktails.
The data signals to investors that the Swiss company can be ready for the loss of patent protection on its primary earner with the introduction of another blockbuster.
The contracting coup comes four months after Amgen tied up with Watson on an ambitious pact to develop biosimilars of some leading cancer therapies.
Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.
Roche has turned in positive data from a key Phase III study of its blockbuster hopeful T-DM1.